Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Rating of “Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been given a consensus rating of “Buy” by the ten ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $53.89.

Several equities analysts recently issued reports on VERA shares. Scotiabank assumed coverage on Vera Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price target on the stock. Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. JPMorgan Chase & Co. lifted their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday. Guggenheim increased their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 15,625 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the sale, the chief executive officer now directly owns 307,972 shares in the company, valued at approximately $11,548,950. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $48.03, for a total transaction of $720,450.00. Following the transaction, the director now owns 131,553 shares in the company, valued at $6,318,490.59. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $11,548,950. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,398 shares of company stock worth $4,376,163. 21.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after purchasing an additional 350 shares during the period. Public Employees Retirement Association of Colorado bought a new stake in Vera Therapeutics in the 2nd quarter valued at approximately $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vera Therapeutics in the 2nd quarter valued at approximately $163,000. Ameritas Investment Partners Inc. boosted its position in Vera Therapeutics by 20.8% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after acquiring an additional 688 shares during the last quarter. Finally, Cetera Advisors LLC bought a new position in shares of Vera Therapeutics during the 1st quarter worth approximately $235,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $47.94 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43. The firm has a 50 day simple moving average of $40.86 and a 200 day simple moving average of $38.97. Vera Therapeutics has a fifty-two week low of $9.99 and a fifty-two week high of $50.78. The firm has a market cap of $2.63 billion, a P/E ratio of -21.69 and a beta of 1.03.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Sell-side analysts predict that Vera Therapeutics will post -2.57 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.